Clinical trial
Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of…
NCT00318448 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00318448 |
|---|---|
| Title | Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia |
| Official title | Efficacy, Safety and Tolerability of Zolpidem in the Treatment of Children Aged 6 to 17 Years With ADHD-Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study |
| Acronym | Zolkids |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Zolpidem (SL800750) |
| Enrollment | 201 |
| Start date | Apr 1, 2006 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Apr 26, 2006 |
| Last update posted | Apr 7, 2009 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: